Progesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases

1993 ◽  
Vol 25 (1) ◽  
pp. 47-55 ◽  
Author(s):  
E. M�ller-Holzner ◽  
A. G. Zeimet ◽  
G. Daxenbichler ◽  
C. Marth ◽  
L. C. M�ller ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastases ◽  
Progesterone Receptors ◽  
Breast Carcinomas ◽  
Node Metastases

FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases

2005 ◽  
Vol 200 (11-12) ◽  
pp. 743-751 ◽  
Author(s):  
Harry L. Ioachim ◽  
Ramona Decuseara ◽  
Francesca Giancotti ◽  
Brent H. Dorsett
Keyword(s):  
Lymph Node ◽  
Tumor Cells ◽  
Lymph Node Metastases ◽  
Breast Carcinomas ◽  
Node Metastases ◽  
Fas L

scholarly journals Triple Negative Breast Carcinoma: A Comparative Study between Breast Lesion and Lymph Node Metastases: A Preliminary Study

2011 ◽  
Vol 2011 ◽  
pp. 1-6
Author(s):  
David Parada ◽  
Karla Peña ◽  
Francesc Riu ◽  
Pilar Hernandez
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Lymph Node Metastases ◽  
Triple Negative ◽  
Axillary Lymph ◽  
Breast Carcinomas ◽  
Variable Expression ◽  
Basal Marker ◽  
Triple Negative Breast Carcinoma ◽  
Node Metastases

Aims and Background. Triple negative breast carcinoma is a genetic and molecular subtype of breast carcinoma with poor prognosis. Some immunohistochemistry studies have been proposed to identify BLBC. Most studies consider primary breast carcinoma but not metastases. Methods. Immunohistochemical characteristics in 11 triple negative breast carcinomas were studied in both primary lesions and lymph node metastases. All cases were reevaluated to estrogen and progesterone receptors and HER2-Neu. An FISH probe for HER2/neu was also performed. Immunohistochemical studies were performed with cytokeratin 5/6, 17, Cam 5.2, p63, EGFR, and Ki-67 in breast carcinoma and lymph node metastases. Results. The age of the patients ranged between 42 and 73 years (mean 53), and the mean followup was 68.25 months. A total of 54.55% of the patients were disease-free, and 45.45% died of carcinoma. Axillary lymph nodes maintained triple negative phenotype (11/11). Metastatic tumors showed CAM 5.2 (81.83%) and EGFR (72.73%) expression. Basal marker expression was variable in primary carcinoma and lymph node metastases (63.64%). Conclusions. Triple negative breast carcinomas maintained this immunoprofile at lymph node metastases. Triple negative carcinomas showed variable expression of basal cell markers.

Sign in / Sign up

Export Citation Format

Share Document